Back to News
Apr 9, 2026 4:00 PM

Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline

Gilead Sciences Inc. (NASDAQ:GILD) is deepening its oncology strategy through expanded partnerships with Tempus AI Inc. (NASDAQ:TEM) and Kymera Therapeutics Inc. (NASDAQ:KYMR), combining data-driven insights with pipeline development efforts.

The company broadened its multi-year collaboration with Tempus to enhance oncology research and development.

At the same time, it exercised an option to license Kymera's investigational candidate KT-200, signaling continued investment in cancer therapies.

Expanded Tempus Deal Enhances Data-Driven Oncology Strategy

Gilead has already been utilizing Tempus' de-identified multimodal data repository across several oncology initiatives.

These include clinical trial design, biomarker strategies, indication selection, and real-world evidence generation.

Under the expanded agreement, Gilead gains enterprise-wide access to Tempus' AI-powered Lens platform.

The platform is expected to provide ...